Key Points
- CTO Abhimanyu Verma sold 5,000 SOPHiA GENETICS shares at an average price of $8.20, generating $41,000 and reducing his direct holdings by 2.74% to 177,171 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 plan.
- SOPH shares opened at $8.53, near their 52-week high of $8.85, with the stock up significantly from its 52-week low of $3.10. The company reported quarterly revenue of $23.31 million, above estimates, but missed earnings expectations with a loss of $0.26 per share.
- Analyst sentiment is mixed: three analysts rate the stock Buy, one rates it Hold and one Sell, producing an overall “Hold” consensus and an average price target of $10.00. Multiple analysts recently raised their targets, while several insiders have sold shares.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $8.20, for a total value of $41,000.00. Following the completion of the sale, the chief technology officer directly owned 177,171 shares of the company's stock, valued at approximately $1,452,802.20. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Abhimanyu Verma also recently made the following trade(s):
- On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.80, for a total value of $44,000.00.
- On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total value of $38,000.00.
- On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.
- On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total transaction of $26,953.50.
- On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44.
SOPHiA GENETICS Stock Performance
Shares of SOPH stock opened at $8.53 on Thursday. SOPHiA GENETICS SA has a 52 week low of $3.10 and a 52 week high of $8.85. The company has a market capitalization of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.96. The company has a 50-day simple moving average of $6.39 and a 200 day simple moving average of $5.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the company. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. HC Wainwright boosted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $10.00.
Get Our Latest Stock Analysis on SOPH
Key Stories Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: The stock reached a new 12-month high, signaling strong recent momentum and investor interest. SOPHiA GENETICS Sets New 12-Month High
- Neutral Sentiment: Reported short interest was zero shares as of August 25, implying no measurable short-selling pressure. The data also showed no meaningful change from the prior period, limiting its usefulness as a trading signal.
- Negative Sentiment: CTO Abhimanyu Verma sold 5,000 shares for approximately $44,000 on August 24, reducing his position by 2.82%. Because the sale followed a pre-arranged Rule 10b5-1 plan, it may not reflect a current change in the executive’s outlook. SEC Form 4 filing
- Negative Sentiment: Director Kathy L. Hibbs sold 6,250 shares worth about $54,250 on August 25, decreasing her holdings by 5.71%. The sale adds to near-term insider-selling concerns but was also executed under a 10b5-1 plan. SEC Form 4 filing
- Negative Sentiment: Insider Philippe Menu sold 5,000 shares for approximately $43,400 on August 25, reducing his position by 2.29%. The transaction was pre-planned, which moderates—but does not eliminate—the potential negative signal from multiple insider sales. SEC Form 4 filing
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the first quarter worth about $1,772,000. AWM Investment Company Inc. acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. 1492 Capital Management LLC acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $973,000. Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Institutional investors own 31.59% of the company's stock.
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
